EN 
RO 
HU Oncompass
Oncompass Medicine has been developing unique medical technology internationally for 15 years, with the help of which the treatment of oncology patients has become more and more targeted and successful.
Personalized treatment based on molecular genetics information, more precisely precision treatment, is appearing more and more rapidly in current medical practice. While in the past 10-20 products reached the market during a decade, in the last 5 years their number was 63 and last year alone 14 new molecularly targeted treatments were reached. The personalized application of the right drugs from a molecular diagnostic point of view has become a tremendous challenge. Oncompass Medicine is committed to making its patients benefit from this historic, unprecedented technological development.
The company was founded by two doctors in 2003, and currently has more than 50 employees, who helped more than 1000 patients in 2017.
Oncompass Medicine employees successfully treated a lung tumor patient for the first time in the world, in a documented way, based on the molecular target (1) and demonstrated that examining genetic changes can predict treatment response (2). For the first time, they applied molecular diagnostic tests involving several genes, through whose bioinformatic analysis the most suitable treatment can be searched for and found for the patient in question, regardless of the type of tumor (3).
Dr. Peták István, who is director and founding member of Oncompass Medicine, is the author of more than 70 scientific publications and in 2012 received the Gábor Dénes Award for Personalized Treatment. Since 2017, he has become the guest of honor of the largest medical faculty – University of Illinois at Chicago (UIC), where he gives presentations. In 2017 he was contacted as a lecturer by ESMO (European Society of Medical Oncology), in 2018 by ISO (Indian Society of Oncology) and by CCI (Childhood Cancer International).
In 2016, at the 10th Personalized Medicine World Conference (PMWC) in Silicon Valley, Oncompass Medicine presented its AI-based medical software, which currently selects from over 1000 drugs on the most appropriate, based on genetic changes in the patient’s tumor, taking into account over 400 tumor types and over 22,000 medical protocols.
Since 2017, Oncompass Medicine has become a partner of the consortium of the South Budapest Central Hospital and the National Institute of Oncology in Hungary, within the National Program for Precision Oncology and Innovative Oncogenomics Based Oncology, which is carried out through the National Program for Competitiveness and Excellence .
The goal of Oncompass Medicine is to help as many patients as possible to find personalized treatments both in the country and abroad.
- Contact person: Dr. Peták István, founder, scientific director and general manager.
- Contact person in Sf. Gheorghe, at Pro-Vitam: Dr. Terza Livia-Maria
Modern treatment of lung cancer. Case 1. Amplification and mutation of the epidermal growth factor receptor in metastatic lung cancer with remission from gefitinib. Schwab R et al. J Clin Oncol. 2005 Oct 20;23(30):7736-8 Epidermal growth factor receptor (EGFR) high gene copy number and activating mutations in lung adenocarcinomas are not consistently accompanied by positivity for EGFR protein by standard immunohistochemistry. Pinter F et al. J Mol Diagn. 2008 Mar;10(2):160-8.3. 3. Integrating molecular diagnostics into anticancer drug discovery. Peták I at al. Nat Rev Drug Discov. 2010 Jul;9(7):523-35.